ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026
Evaluation of Tissue from Patients with Prostate Cancer Identifies B7-H3 as an Androgen-Regulated, Broadly Expressed, Combinatorial Therapeutic Target.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
purposeAdvanced prostate cancer management suffers from therapeutic resistance due to naturally transient or androgen receptor (AR)-dependent expression of clinically actionable surface targets. We aimed to identify the most promising clinically relevant prostate cancer targets using RNA and protein expression levels across the prostate cancer continuum-hormone-sensitive, castration-resistant, neuroendocrine, and "double-negative" prostate cancer. EXPERIMENTAL
designWe performed integration of a large single-cell transcriptomics atlas (JHU-PANORAMA, ∼1 million cells and 213 patients) and patient-derived xenograft models for the systematic investigation of the clinically relevant surfaceome, followed by proteomic validation on patient samples and mechanistic investigations on prostate cancer cell lines and patient samples.
resultsB7 homolog 3 (B7-H3) was found to be the most uniformly expressed across the entire prostate cancer continuum. JHU-PANORAMA is made available for interactive visualization as an R Shiny web app. Further mitigation of therapeutic resistance is proposed through a systematic framework for bispecific antibody design, in which B7-H3 demonstrates high combinatorial scores with TROP-2, NECTIN1, KLK2, and NECTIN4. B7-H3 was also shown to be negatively regulated by AR and synergistically inhibit tumor growth when combined with androgen inhibition.
conclusionsB7-H3 demonstrates low interpatient and intratumoral heterogeneity, with significant synergistic effects in combination with AR inhibition. These properties could uniquely position B7-H3 as a broad-spectrum therapeutic target, with the potential to combine B7-H3 based therapeutics with standard androgen deprivation therapy for synergistic effects to overcome therapeutic resistance across the prostate cancer disease continuum. See related article by Makovec et al., p. 3381.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.